Pfizer: European Commission Approves BAVENCIO Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
October 28, 2019
October 28, 2019
DARMSTADT, Germany, Oct. 28 -- Pfizer, a pharmaceutical company, issued the following news release:
Darmstadt, Germany and New York, US, - Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved BAVENCIO(R) (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Th . . .
Darmstadt, Germany and New York, US, - Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved BAVENCIO(R) (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Th . . .